Appendix 4E & 2026 Full Year Statutory Accounts
Filed with ASX · · 93 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue attributed to a licensing agreement, but also notes a substantial increase in losses due to rising research and development expenses. Additionally, the company reported no dividends for the current financial period and provided insights into its ongoing clinical trials and strategic partnerships.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- Immutep Quarterly Activities Report Q4 FY26
- Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
- Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
- Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
- Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Later from Immutep
- S&P DJI Announces September 2026 Quarterly Rebalance
- Immutep Outlines Focused Development Strategy for Efti
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
- Change to American Depositary Share Ratio
- Immutep Receives ~A$0.86 Million R&D Tax Incentive
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep